Protective effects of DA-9805 on dopaminergic neurons against 6-hydroxydopamine-induced neurotoxicity in the models of Parkinson’s disease - 31/07/19

pages | 9 |
Iconographies | 8 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | DA-9805 treatment attenuates 6-OHDA-induced motor dysfunctions. |
• | DA-9805 treatment reduces 6-OHDA-induced damage of dopaminergic neurons. |
• | DA-9805 has protective effects via activating ERK/Nrf2 signaling pathway. |
Abstract |
With the elderly population rapidly growing, the prevalence of Parkinson’s disease (PD) is quickly increasing because neurodegenerative disorders are usually late-onset. Herbal medicines and formula are adjuvant therapies of conventional PD agents, which result in serious side effects with long-term use. This study evaluated the neuroprotective effects of DA-9805, a standardized herbal formula that consists of an ethanolic extract of Moutan Cortex Radix, Angelica Dahuricae Radix, and Bupleuri Radix against 6-hydroxydopamine (6-OHDA)-induced cytotoxicity in vitro and in vivo. In PC12 cells, DA-9805 at concentrations of 1 and 10 μg/mL ameliorated cell viability, which was reduced by 6-OHDA. In addition, DA-9805 activated the extracellular-regulated kinase-nuclear transcription factor-erythroid 2-related factor 2 pathway, subsequently stimulating antioxidative enzymes such as NAD(P)H:quinone oxidoreductase 1 and catalase and suppressing apoptosis. Furthermore, DA-9805 prevented 6-OHDA-induced movement impairment, as well as a decrease of dopaminergic neurons and dopamine transmission in rodents. Taken together, these results suggest that the mixed herbal formula DA-9805 may be a pharmaceutical agent for preventing or improving PD.
Le texte complet de cet article est disponible en PDF.Abbreviations : PD, SNpc, ST, Nrf2, ERK, CAT, NQO1, Bcl-2, MC, ADR, BR, RPMI, P/S, FBS, MTT, PFA, DAB, BSA, PBS, TH, DAT, p-ERK, PCNA, ABC, SEM, ANOVA
Keywords : DA-9805, Parkinson’s disease, 6-Hydroxydopamine, Nuclear factor (erythroid-derived 2)-like 2, Extracellular regulated kinase
Plan
Vol 117
Article 109184- septembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?